

Metabolic Syndrome

Bibliography of One Hundred Key Papers

selected by **Brent M. Egan, MD; Stevo Julius, MD, ScD**

Medical University of South Carolina, SC (B. M. E.)

University of Michigan - Ann Arbor, Mich (S. J.) - USA

-
- Alberti KGMM, Zimmet PZ.** *Diagnosis and classification of diabetes mellitus: Part I—provisional report of a WHO consultation.*
Diabetes Med. 1998;15:539-553.
-
- Anderson EA, Balon TW, Hoffman RP, Sinkey CA, Mark AL.** *Insulin increases sympathetic activity but not blood pressure in borderline hypertensive humans.*
Hypertension. 1992;19:621-627.
-
- Andersson B, Elam M, Wallin BG, Björntorp P, Andersson OK.** *Effect of energy-restricted diet on sympathetic muscle nerve activity in obese women.*
Hypertension. 1991;18:783-789.
-
- Balasubramaniam A.** *Clinical potential of neuropeptide Y family of hormones.*
Am J Surg. 2002;183:430-434.
-
- Bastard JP, Pieroni L, Hainque B.** *Relationship between plasma plasminogen activator inhibitor-1 and insulin resistance.*
Diab Metab Res Rev. 2000;16:192-201.
-
- Bouloux PM, Grossman A, Al-Damluji S, Bailey T, Besser M.** *Enhancement of the sympathoadrenal response to the cold-pressor test by naloxone in man.*
Clin Sci. 1985;69:365-368.
-
- Brody MJ, Kadowitz PJ.** *Prostaglandins as modulators of the autonomic nervous system.*
Fed Proc. 1974;33:48-60.
-
- Bülow J, Madsen J, Hojgaard L.** *Reversibility of the effects on local circulation of high lipid concentrations in blood.*
Scand J Clin Lab Invest. 1990;50:291-296.
-
- Bunker CH, Ukoli FA, Matthews KA, Kriska AM, Huston SL, Kuller LH.** *Weight threshold and blood pressure in a lean black population.*
Hypertension. 1995;26:616-623.
-
- Cabezas MC, deBruin TWA, deValk HW, et al.** *Impaired fatty acid metabolism in familial combined hyperlipidemia. A mechanism associating apolipoprotein B overproduction and insulin resistance.*
J Clin Invest. 1993;92:160-168.
-
- Carroll JF, Hunag M, Hester RL, Cockrell K, Mizelle HL.** *Hemodynamic alterations in hypertensive obese rabbits.*
Hypertension. 1995;26:465-470.
-

Bibliography of One Hundred Key Papers

- Chan JC, Cheung JC, Stehouwer CD, et al.** *The central roles of obesity-associated dyslipidaemia, endothelial activation and cytokines in the Metabolic Syndrome—an analysis by structural equation modeling.* **Int J Obes.** 2002;26:994-1008.
-
- Egan BM.** *Insulin resistance and the sympathetic nervous system.* **Curr Hypertens Rep.** 2003;5:247-254.
-
- Egan B, Panis R, Hinderliter A, Schork N, Julius S.** *Mechanism of increased α -adrenergic vasoconstriction in human essential hypertension.* **J Clin Invest.** 1987;80:812-817.
-
- Egan BM, Stepniakowski K, Goodfriend TL.** *Renin and aldosterone are higher and the hyperinsulinemic effects of salt restriction greater in subjects with risk factor clustering.* **Am J Hypertens.** 1994;7:886-893.
-
- Emdin M, Gastaldelli A, Muscelli E, et al.** *Hyperinsulinemia and autonomic nervous system dysfunction in obesity: effects of weight loss.* **Circulation.** 2001;103:513-519.
-
- Engeli S, Sharma AM.** *Role of adipose tissue for cardiovascular-renal regulation in health and disease.* **Horm Metab Res.** 2000;21:485-499.
-
- Esler M, Ferrier C, Lambert G, Eisenhofer G, Cox H, Jennings G.** *Biochemical evidence of sympathetic hyperactivity in human hypertension.* **Hypertension.** 1991;17(suppl III):III29-III35.
-
- Esler M, Magdalena R, Wiesner G, Kaye D, Hasting J, Lambert G.** *Sympathetic nervous system and insulin resistance: from obesity to diabetes.* **Am J Hypertens.** 2001;14:304S-309S.
-
- Esler M, Zweifler A, Randall O, Julius S, DeQuattro V.** *The determinants of plasma-renin activity in essential hypertension.* **Ann Int Med.** 1978;88:746-752.
-
- Esposito K, Pontillo A, Di Pala C, et al.** *Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial.* **JAMA.** 2003;289:1799-1804.
-
- Expert Panel ATP III.** *Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III).* **JAMA.** 2001;285:2486-2497.
-
- Facchini FS, Hua NW, Reaven GM, Stoohs RA.** *Hyperinsulinemia: the missing link among oxidative stress and age-related diseases?* **Free Radic Biol Med.** 2000;29:1302-1306.
-
- Fagot-Campagna A, Balkau B, Simon D, et al.** *High free fatty acid concentration: an independent risk factor for hypertension in the Paris Prospective Study.* **Int J Epidemiol.** 1998;27:808-813.
-
- Ferrannini E, Barrett EJ, Bevilacqua S.** *Effects of fatty acids on glucose production and utilization in man.* **J Clin Invest.** 1983;72:1737-1747.
-
- Ferrannini E, Natali A, Bell P, Cavallo-Perin P, Lalic N, Mingrone G.** *Insulin resistance and hypersecretion in obesity.* **J Clin Invest.** 1997;100:1166-1173.
-



-
- Field AE, Coakley EH, Must A, et al.** *Impact of overweight on the risk of developing common chronic diseases during a 10-year period.*
Arch Intern Med. 2001;161:1581-1586.
-
- Flegal KM, Carroll MD, Ogden CL, Johnson CL.** *Prevalence and trends in obesity among US adults, 1999-2000.*
JAMA. 2002;288:1723-1727.
-
- Fletcher EC, Lesske J, Behm R, Miller CC 3rd, Stauss H, Unger T.** *Carotid chemoreceptors, systemic blood pressure, and chronic episodic hypoxia mimicking sleep apnea.*
J Appl Physiol. 1992;1978-1984.
-
- Ford ES, Giles WH, Dietz WH.** *Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey.*
JAMA. 2002;287:356-359.
-
- Gadegbeku CA, Dhandayuthapani A, Sadler JE, Egan BM.** *Raising lipids acutely reduces baroreflex sensitivity.*
Am J Hypertension. 2002;15:479-485.
-
- Gao YY, Lovejoy, Spart AN, Gray GA, Keys LK, Partington C.** *Autonomic activity assessed by heart rate spectral analysis varies with fat distribution in obese women.*
Obes Res. 1996;4:55-63.
-
- Garfinkel L.** *Overweight and cancer.*
Ann Int Med. 1985;103(6, pt 2):1034-1036.
-
- Gidding SS, Falkner B.** *Are we losing the game? Cardiovascular health in minority children.*
Ethnic Dis. 2002;12:171-173.
-
- Grassi G, Seravalle G, Colombo M, et al.** *Body weight reduction, sympathetic nerve activity, and arterial baroreflex in obese normotensive humans.*
Circulation. 1998;97:2037-2042.
-
- Grassi G, Seravalle G, Dell'Orio R, et al.** *Participation of the hypothalamus-hypophysis axis in the sympathetic activation of human obesity.*
Hypertension. 2001;38:1316-1320.
-
- Grassi G, Seravalle G, Dell-Oro R, Turri C, Bolla GB, Mancia G.** *Adrenergic and reflex abnormalities in obesity-related hypertension.*
Hypertension. 2000;36:538-542.
-
- Grekin RJ, Dumont CJ, Vollmer AP, Watts SW, Webb RC.** *Mechanisms in the pressor effects of hepatic portal venous fatty acid infusion.*
Am J Physiol. 1997;273:R324-R330.
-
- Guyton AC.** *Blood pressure control—special role of the kidneys and body fluids.*
Science. 1991;252:1813-1816.
-
- Haastrup T, Stepniakowski KT, Goodfriend TL, Egan BM.** *Lipids enhance α_1 -adrenergic receptor mediated pressor reactivity.*
Hypertension. 1998;32:693-698.
-
- Hall JE, Brands MW, Hildebrandt DA, Kuo J, Fitzgerald S.** *Role of sympathetic nervous system and neuropeptides in obesity hypertension.*
Braz J Med Biol Res. 2000;33:605-618.
-
- Hausberg M, Hoffman RP, Somers VK, Sinkey CA, Mark AL, Anderson EA.** *Contrasting autonomic and hemodynamic effects of insulin in health elderly versus young subjects.*
Hypertension. 1997;29:700-705.
-

Bibliography of One Hundred Key Papers

- Heitmann BL.** *Body fat distribution in the adult Danish population aged 35-65 years: an epidemiological study.*
Int J Obes. 1991;58:535-545.
-
- Hildebrandt DA, Kirk D, Hall JE.** *Renal and cardiovascular responses to chronic increases in cerebrovascular free fatty acids.*
Fed Proc. 1999;13:780. Abstract and personal communication.
-
- Hirsch J, Leibel RL, Mackintosh R, Aguirre A.** *Heart rate variability as a measure of autonomic function during weight change in humans.*
Am J Physiol. 1991;261:R1418-R1423.
-
- Hwang IS, Ho H, Hoffman BB, Reaven GM.** *Fructose-induced insulin resistance and hypertension in rats.*
Hypertension. 1987;10:512-516.
-
- Jamerson KA, Julius S, Gudbrandsson T, Andersson O, Brant DO.** *Reflex sympathetic activation induces acute insulin resistance in the human forearm.*
Hypertension. 1993;21:618-623.
-
- Jensen MD, Haymond MW, Rizza RA, Cryer PE, Miles JM.** *Influence of body fat distribution on free fatty acid metabolism in obesity.*
J Clin Invest. 1989;83:1168-1173.
-
- Johnson EH.** *Interrelationships between psychological factors, overweight, and blood pressure in adolescents.*
J Adolesc Health Care. 1990;11:310-318.
-
- Jones PP, Snitker S, Skinner JS, Ravussin E.** *Gender differences in muscle sympathetic nerve activity: effect of body fat distribution.*
Am J Physiol. 1996;270:E363-E366.
-
- Jouven X, Charles MA, Desnos M, Ducimetière P.** *Circulating nonesterified fatty acid level as a predictive risk factor for sudden death in the population.*
Circulation. 2001;104:756-761.
-
- Julius S, Esler M.** *Autonomic nervous cardiovascular regulation in borderline hypertension.*
Am J Cardiol. 1975;36:685-696.
-
- Julius S, Majahalme S.** *The changing face of sympathetic overactivity in hypertension.*
Ann Med. 2000;32:365-370.
-
- Julius S, Palatini P, Nesbitt SD.** *Tachycardia: an important determinant of coronary risk in hypertension.*
J Hypertens. 1998;16(suppl 1):S9-S15.
-
- Julius S, Valentini M, Palatini P.** *Overweight and hypertension—a two way street?*
J Hypertens. 2000;35:807-813.
-
- Kissebah AH, Krakower GR.** *Regional adiposity and morbidity.*
Physiol Rev. 1994;74:761-811.
-
- Konishi S, Tsunoo A, Otsuka M.** *Enkephalins presynaptically inhibit cholinergic transmission in sympathetic ganglia.*
Nature. 1979;282:515-516.
-



-
- Kunsch C, Medford RM.** *Oxidative stress as a regulator of gene expression in the vasculature.* **Circ Res.** 1999;85:753-766.
-
- Kuo JJ, Jones OB, Hall JE.** *Inhibition of NO synthesis enhances chronic cardiovascular and renal actions of leptin.* **Hypertension.** 2001;37(pt 2):670-676.
-
- Laakso M, Edelman SV, Brechtel G, Baron AD.** *Decreased effect of insulin to stimulate skeletal muscle blood flow in obese man.* **J Clin Invest.** 1990;85:1844-1852.
-
- Laaksonen DE, Lakka HM, Niskanen LK, Kaplan GA,** *Metabolic syndrome and development of diabetes mellitus: application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study.* **Am J Epidemiol.** 2002;156:1070-1077.
-
- Lakka HM, Laaksonen DE, Lakka TA, et al.** *The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men.* **JAMA.** 2002;288:2790-2716.
-
- MacMahon SW, Blacket RB, Macdonald GJ, Hall W.** *Obesity, alcohol consumption and blood pressure in Australian men and women. The National Heart Foundation of Australia Risk Factor Prevalence Study.* **J Hypertens.** 1984;2:85-91.
-
- Maguri SR, Hauser R, Schwartz J, Williams PL, Smith TJ, Christiani DC.** *Association of heart rate variability with occupational and environmental exposure to particulate air pollution.* **Circulation.** 2001;104:986-991.
-
- Mark AL, Correia M, Morgan DA, Shaffer RA, Haynes WG.** *State-of-the-art lecture: obesity-induced hypertension: new concepts from the emerging biology of obesity.* **Hypertension.** 1999;33(pt 2):537-541.
-
- Masuo K, Mikami H, Ogihara T, Tuck ML.** *Sympathetic nerve hyperactivity precedes hyperinsulinemia and blood pressure elevation in young nonobese Japanese population.* **Am J Hypertens.** 1997;10:77-83.
-
- McCubbin JA, Surwit RS, Williams RB, Nemeroff CB, McNeilly M.** *Altered pituitary hormone response to naloxone in hypertension development.* **Hypertension.** 1989;14:636-644.
-
- Mokdad AH, Ford ES, Bowman BA, et al.** *Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001.* **JAMA.** 2003;289:76-79.
-
- Monroe MB, Van Pelt RE, Schiller BC, Seals DR, Jones PP.** *Relation of leptin and insulin to adiposity-associated elevations in sympathetic activity with age in humans.* **Int J Obes.** 2000;24:1183-1187.
-
- Neutel JM, Smith DH, Graettinger WFC, Winer RL, Weber MA.** *Heredity and hypertension: impact on metabolic characteristics.* **Am Heart J.** 1992;124:435-440.
-
- O'Dea K, Esler M, Leonard P, Stockigt JR, Nestel P.** *Noradrenaline turnover during under- and over-eating in normal weight subjects.* **Metabolism.** 1982;31:896-899.
-

Bibliography of One Hundred Key Papers

- Paolisso G, Manzella D, Rosaria MR, et al.** *Elevated plasma fatty acid concentrations stimulate the cardiac autonomic nervous system in healthy subjects.*
Am J Clin Nutr. 2000;72:723-730.
-
- Paquali R, Cantobelli S, Casimirri F, et al.** *The role of opioid peptides in the development of hyperinsulinemia in obese women with abdominal fat distribution.*
Metabolism. 1992;41:763-767.
-
- Park YW, Zhu S, Palaniappan L, Heshka S, Carnethon MR, Hemsfield SB.** *The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994.*
Arch Intern Med. 2003;163:427-436.
-
- Pollare T, Lithell H, Selinus I, Berne C.** *Application of prazosin is associated with an increase of insulin sensitivity in obese patients with hypertension.*
Diabetologia. 1988;31:415-420.
-
- Prebble WE.** *Obesity: observations on one thousand cases.*
Boston Med Surg J. 1923;88:617-621.
-
- Qadri F, Carretero OA, Scicli AG.** *Centrally produced nitric oxide in the control of baroreceptor reflex sensitivity and blood pressure in normotensive and hypertensive spontaneously hypertensive rats.*
Jpn J Pharmacol. 1999;81:279-285.
-
- Quesenberry CP, Caan B, Jacobson A.** *Obesity, health services use, and health care costs among members of a health maintenance organization.*
Arch Int Med. 1998;158:466-472.
-
- Quillot D, Fluckiger L, Zannad F, Drouin P, Ziegler O.** *Impaired autonomic control of heart rate and blood pressure in obesity: role of age and of insulin-resistance.*
Clin Auton Res. 2001;11:79-86.
-
- Ramirez-Gonzalez MD, Tchakarov L, Garcia RM, Kunos G.** *β -Endorphin acting on the brainstem is involved in the antihypertensive action of clonidine and α -methyl dopa in rats.*
Circ Res. 1983;53:150-157.
-
- Reaven GM.** *Pathophysiology of insulin resistance in human disease.*
Physiol Rev. 1995;75:473-486.
-
- Reaven GM, Hollenbeck C, Jeng CY, Wu MS, Chen YDI.** *Measurement of plasma glucose, free fatty acids, lactate, and insulin for 24 hours in patients with NIDDM.*
Diabetes. 1988;37:1020-1024.
-
- Ries DJ, Morrison S, Ruggiero DA.** *The C1 area of the brainstem in tonic and reflex control of blood pressure: state of the art lecture.*
Hypertension. 1988;11(suppl 1):I8-I13.
-
- Rocchini AP, Key J, Bondie D, et al.** *The effect of weight loss on the sensitivity of blood pressure to sodium in obese adolescents.*
N Engl J Med. 1989;321:580-585.
-
- Rocchini AP, Mao HZ, Babu K, Marker P, Rocchini AJ.** *Clonidine prevents insulin resistance and hypertension in obese dogs.*
Hypertension. 1999;33(pt 2):548-553.
-



-
- Rothman RB, Xu H, Char GU, et al.** *Phenylpiperidine opioid antagonists that promote weight loss in rats have high affinity for the $\kappa 2B$ (enkephalin-sensitive) binding site.* **Peptides.** 1993;14:17-20.
-
- Rothwell NJ.** *Central regulation of thermogenesis.* **Crit Rev Neurobiol.** 1994;8:1-10.
-
- Roux F, D'Ambrosio C, Mohsenin V.** *Sleep-related breathing disorders and cardiovascular disease.* **Am J Med.** 2000;108:396-402.
-
- Rowley K, O'Dea K, Best JD.** *Association of albuminuria and the metabolic syndrome.* **Curr Diab Rep.** 2003;3:80-86.
-
- Silverberg DS, Oksenberg A.** *Are sleep-related breathing disorders important contributing factors to the production of essential hypertension?* **Curr Hypertens Rep.** 2001;3:209-215.
-
- Snitker S, Macdonald I, Ravussin E, Astrup A.** *The sympathetic nervous system and obesity: role in aetiology and treatment.* **Obes Rev.** 2000;1:5-15.
-
- Sower JR, Nyby M, Stern N, et al.** *Blood pressure and hormone changes associated with weight reduction in the obese.* **Hypertension.** 1982;4:686-691.
-
- Steinberg HO, Tarshoby M, Monestel R, et al.** *Elevated circulating free fatty acid levels impair endothelium-dependent vasodilation.* **J Clin Invest.** 1997;100:1230-1239.
-
- Stern M, Haffner S.** *Body fat distribution and hyperinsulinemia as risk factors for diabetes and cardiovascular disease.* **Arteriosclerosis.** 1986;6:123-129.
-
- Stjärne L.** *Enhancement by indomethacin of cold-induced hypersecretion of noradrenaline in the rat in vivo by suppression of PGE mediated feedback control?* **Acta Physiol Scand.** 1972;86:388-397.
-
- Stojiljkovic MP, Zhang D, Lopes HF, Lee CG, Goodfriend TL, Egan BM.** *Hemodynamic effects of lipids in humans.* **Am J Physiol.** 2001;280:1674-1679.
-
- Strauss RS, Pollack HA.** *Epidemic increase in childhood overweight, 1986-1998.* **JAMA.** 2001;286:2845-2848.
-
- Tanioka H, Nakamura K, Fujimura S, et al.** *Facilitatory role of NO in neural norepinephrine release in the rat kidney.* **Am J Physiol.** 2002;282:R1436-R1442.
-
- The European Group for the Study of insulin Resistance (EGIR).** *Frequency of the WHO metabolic syndrome in European cohorts, and an alternative definition of an insulin resistance syndrome.* **Diabetes Metab.** 2002;28:364-376.
-
- Thomas GD, Sander M, Lau KS, Huang PL, Stull JT, Victor RG.** *Impaired metabolic modulation of alpha-adrenergic vasoconstriction in dystrophin-deficient skeletal muscle.* **Circulation.** 1991;83:1849-1865.
-

Bibliography of One Hundred Key Papers

-
- Tuck ML.** *Obesity, the sympathetic nervous system, and essential hypertension.*
Hypertension. 1992;19(suppl 1):I67-I77.
-
- Vgontzas AN, Papanicolaou DA, Bixler EO, et al.** *Sleep apnea and daytime sleepiness and fatigue: relation to visceral obesity, insulin resistance, and hypercytokinemia.*
J Clin Endocrinol Metab. 2000;85:1151-1158.
-
- Wilson PWF, D'Agostino RB, Parise H, Meigs JB.** *The metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus.*
Diabetes. 2002;51(suppl 2):A242.
-
- Wofford MR, Anderson DC, Brown CA, Jones DW, Miller ME, Hall JE.** *Antihypertensive effect of α - and β -adrenergic blockade in obese and lean hypertensive subjects.*
Am J Hypertens. 2001;14:694-698.
-
- Wolf AM, Colditz GA.** *Current estimates of the economic cost of obesity in the United States.*
Obes Res. 1998;6:97-106.
-
- Wollenweider P, Tappy L, Randin D, et al.** *Differential effects of hyperinsulinemia and carbohydrate metabolism on sympathetic nerve activity and muscle blood flow in humans.*
J Clin Invest. 1993;92:147-154.
-

Instructions for authors

GENERAL INSTRUCTIONS

- Manuscripts should be provided on word-processor disks (3.5-in, for IBM, IBM-compatible, or Apple computers) with three hard copies (text and figures) printed on one side of standard-sized white bond paper, double-spaced, with 2.5-cm margins. Pages must be numbered. **Standard typed page = 25 lines of 75 characters (including spaces) double-spaced, 2.5-cm margins = a total of 275 words per page.**
- All texts should be submitted in English. In the case of translations, the text in the original language should be included.
- On the **title page**, provide title of manuscript (title should be concise, not exceeding 120 characters, including spaces), short running title, keywords, and acknowledgments, as well as full names (first name, middle name(s), and last name) with highest academic degrees (in country-of-origin language), affiliations/address, telephone No., fax No., and E-mail address.
- **Illustrations** (photographs, tables, graphs, figures—high-quality printouts, glossy prints, and/or high-quality scans as jpg files) should be of good quality or professionally prepared, numbered according to their order, with proper orientation indicated (eg, “top,” or “left”), and **SHORT legends** provided, not repetitive of text. As figures and graphs may need to be reduced or enlarged, all absolute values and statistics should be provided. All illustrations should be cited in the text, with distinct numbering for figures and tables. Illustrations will be reproduced in full color only when clearly necessary, eg, images from nuclear medicine or histology.
- Include **HEADINGS** using a consistent style for the various levels of headings, to highlight key points and facilitate comprehension of the text. The Publisher reserves the right to add or delete headings when necessary.
- **Abbreviations** should be used sparingly and expanded at first mention.
- Use **Système International** (SI) units.
- Use **generic names of drugs**.
- All **references** should be cited in the text and **numbered consecutively using superscript arabic numerals**. The author-date system of citation is **NOT** acceptable. “In press” references are to be avoided. In the **bibliography**, titles of journals should be **abbreviated according to the Index Medicus**. All authors should be listed up to six; if there are more, only the first three should be listed, followed by “et al” (*Uniform requirements for manuscripts submitted to biomedical journals*: see www.icmje.org). Where necessary, references will be styled to *Dialogues in Cardiovascular Medicine* copyediting requirements. Authors bear total responsibility for the accuracy and completeness of all references and for correct text citation. Example of style for references:
 1. Ouriel K, Geary K, Green RM, Geary JE, DeWeese JA. Factors determining survival after ruptured abdominal aneurysm. *J Vasc Surg*. 1990;11:493-496.
 2. Darling RC, Brewster DC, Ottinger LW. Autopsy study of unoperated abdominal aortic aneurysms: the case for early resection. *Circulation*. 1977;56(suppl II):II161-II164.
 3. Schulman JL. Immunology of influenza. In: Kilbourne ED, Alfade RT, eds. *The Influenza Viruses and Influenza*. Orlando, Fla: Academic Press Inc; 1975:373-393.
- **Copyediting**: all contributions to *Dialogues in Cardiovascular Medicine* will be styled by the Publisher’s editorial department according to the specifications of the current edition of the *American Medical Association Manual of Style*, Williams & Wilkins. Page proofs will be sent to authors for approval and should be returned within 5 days. If this time is exceeded, changes made by the editorial department will be assumed to be accepted by the author. Authors are responsible for all statements made in their work, including changes made by the editorial department and authorized by the author. The Publisher will edit Editorials, Abstracts, and Seminal Paper Summaries to required size if their length does not comply with specific requirements.
- **Copyright** of articles will be transferred to the Publisher of *Dialogues in Cardiovascular Medicine*. For reproduction

of existing work, it is the author’s responsibility to obtain copyright from the author(s) (including self) and the publisher(s) and provide copies of these authorizations with the manuscript.

LEAD ARTICLE

The lead article should not exceed 25 standard typed pages (maximum 8000 words), including an abstract of no more than 200 words, no more than 50 references, and a minimum of 5 - maximum of 10 illustrations (figures and/or tables). A maximum of 5-10 keywords should be included. **The 3 questions for the respondents should be introduced in or after the conclusion.** A separate list of “**10 references of seminal papers**” as well as a separate list of “**100 Key References**” should be provided.

RESPONDENT ARTICLES

Respondent articles should not exceed 25 standard typed pages (maximum 2500 words), including an abstract of no more than 125 words, no more than 10 references, and a minimum of 3 - maximum of 5 illustrations (figures and tables). A maximum of 5-10 keywords should be included.

SEMINAL PAPER SUMMARIES

Seminal paper summaries take up one page of *Dialogues in Cardiovascular Medicine*: the length of each summary should **IMPERATIVELY** be comprised between 500 and 600 words, ie, **not exceed 3000 characters**. Summaries that are too short or too long will be returned to the author or edited by the Publisher. No figures, tables or references should be included in seminal paper summaries.

FASCINOMA CARDIOLOGICA ARTICLES

Fascinoma Cardiologica articles (*A Lexicon of the Heart; Icons of Cardiology; Plants and the Heart; Trails of Discovery, etc*) should not exceed 2000 words (8 standard typed pages), should include 3 to 5 illustrations (figures and tables), and cite no more than 15 references. A maximum of 5-10 keywords should be included. No abstract.